Ellen Jaeger
YOU?
Author Swipe
View article: Genetic and oncogenic features of RASGRF fusions
Genetic and oncogenic features of RASGRF fusions Open
The identification of recurrent oncogenic drivers has enabled targeted therapeutic strategies for subsets of non-small cell lung carcinoma (NSCLC) and other malignancies. Oncogenic fusions involving the RAS-activating guanine exchange fact…
View article: Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers Open
Purpose: To determine if the risk of clonal hematopoiesis (CH) would be higher among those with germline alterations in homologous recombination repair genes (gHRR) in the four BRCA-associated cancers (breast, ovarian, prostate, pancreas) …
View article: <i>ESR1</i> Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor–Positive Breast Cancer
<i>ESR1</i> Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor–Positive Breast Cancer Open
Purpose: Breast cancers with ESR1 mutations are resistant to antiestrogen therapy. In this study, we aimed to investigate the association of ESR1 mutations with resistance to CDK4/6 inhibitors (CDK4/6i) using real-world data analysis and e…
View article: Supplementary Figure S8 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S8 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S8. Transcription factor analysis in localized prostate cancer versus blood. Log2 fold change of the 20 TFs with most accessible and least accessible binding sites in plasma cell-free DNA (see Fig. 4E, Table S12 and Ta…
View article: Supplementary Figure S3 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S3 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S3. Kaplan-Meier analysis of an additional cohort of 27 patients with oligometastatic mCRPC, stratified by AR enhancer amplification status in plasma cell-free DNA. (A) Progression-free survival, (B) radiographic progr…
View article: Supplementary Figure S9 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S9 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S9. Cell-free DNA methylation analysis of differentially accessible transcription factor binding sites. The box and whisker plots summarize methylation levels in plasma cfDNA from AR/enhancer altered versus wild-type m…
View article: Supplementary Table S1-S14 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Table S1-S14 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Table S1. Patient characteristics. Table S2. Patients-level clinical treatment and outcome details. Table S3. Mutations detected in patient cell-free DNA by EnhanceAR-Seq. Table S4. Copy number alterations detected in patient cell-free DNA…
View article: Supplementary Figure S7 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S7 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR/enhancer altered lethal mCRPC (…
View article: Data from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Data from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Purpose:Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinni…
View article: Supplementary Figure S2 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S2 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor (AR) gene body status and (C,D) AR enhancer region sta…
View article: Supplementary Figure S1 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S1 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.
View article: Supplementary Figure S11 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S11 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA fro…
View article: Supplementary Figure S5 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S5 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S5. Kaplan-Meier survival analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment in 63 mCRPC patients according to (A,B) PTEN copy number loss status in cfDNA, (C,…
View article: Supplementary Figure S4 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S4 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S4. Summary of alterations in biologically relevant pathways found in pre-ARSI plasma cell-free DNA of 63 metastatic castration-resistant prostate cancer patients. ARSI, androgen receptor-signaling inhibitors.
View article: Supplementary Figure S6 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S6 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S6. Kaplan–Meier survival analysis of the 43-patient mCRPC cohort that also underwent genome-wide EM-seq, according to (A,B) AR/enhancer alteration status and (C,D) median-split ichorCNA-based median tumor fraction. p …
View article: Supplementary Figure S10 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Supplementary Figure S10 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA…
View article: Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer Open
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinn…
View article: 12 Concordance Analysis of Tissue and Circulating Tumor DNA (ctDNA) in Renal Cell Carcinoma (RCC): Insights from a Multimodal Real-World Database
12 Concordance Analysis of Tissue and Circulating Tumor DNA (ctDNA) in Renal Cell Carcinoma (RCC): Insights from a Multimodal Real-World Database Open
Background Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) has emerged as a powerful complement to tissue NGS, offering a noninvasive and serially conductible test. Its application holds promise in enhancing the assessmen…
View article: Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database.
Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database. Open
4533 Background: Next generation sequencing (NGS) of ctDNA can complement tissue NGS and is a non-invasive test that can be conducted serially, with the potential to enhance assessment of spatial and temporal molecular tumor heterogeneity.…
View article: Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies
Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies Open
Background: The predictive and prognostic role of BRAF alterations has been evaluated in colorectal cancer (CRC); however, BRAF alterations have not been fully characterized in non-CRC gastrointestinal (GI) malignancies. In the present stu…
View article: Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in<i>AR</i>-altered lethal prostate cancer
Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in<i>AR</i>-altered lethal prostate cancer Open
Summary Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor (AR)-targeted agents is often lethal. Unfortunately, biomarkers for this deadly disease remain under investigation, and underpinning mechanisms …
View article: Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies Open
PURPOSE Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response in patients receiving immune checkpoint inhibitors (ICIs). Here, we perfo…
View article: Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide Open
Background African American men are much more likely than Caucasian men to be diagnosed with and to die of prostate cancer. Genetic differences likely play a role. The cBioPortal database reveals that African American men with prostate can…
View article: Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer
Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer Open
Background Bipolar androgen therapy (BAT) is a novel therapy known to be effective in a subset of men with metastatic castrate resistant prostate cancer (mCRPC). A better understanding of responders and nonresponders to BAT would be useful…
View article: Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab
Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab Open
Background Black men are at higher risk for prostate cancer death. Previous studies showed a benefit of different therapies, including immune-based therapy, for Black men with metastatic prostate cancer. We sought to explore the efficacy o…
View article: Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race Open
Advanced prostate cancer (aPC) in Black men was reported to present with aggressive features and to be associated with poor prognosis. Herein, we compared the cell-free DNA (cfDNA) genomic landscape of aPC in Black vs White men. Patients (…
View article: 3D Printed Solutions for Spheroid Engineering and Cancer Research
3D Printed Solutions for Spheroid Engineering and Cancer Research Open
In multicellular organisms, cells are organized in a 3-dimensional framework and this is essential for organogenesis and tissue morphogenesis. Systems to recapitulate 3D cell growth are therefore vital for understanding development and can…